Advertisement

Genetic Alternations in Common Cancers

  • Fred Bunz
Chapter

Abstract

Each of the roughly 100 types of human cancer is caused by the activation of proto-oncogenes and the loss of tumor suppressor genes. Although cancer genomes are complex, some clear mutational patterns are apparent. Several cancer genes are observed very frequently in some types of cancer, but rarely found in other types. Other cancer genes are much more widespread across many types of cancer. Analysis of many cancer genomes has shown that nearly 150 genes are recurrently altered by mutations to provide tumor cells a selective growth advantage. These studies have shown that there are many potential combinations of cancer genes that can cooperatively allow the growth of different types of neoplasia.

Keywords

Familial Adenomatous Polyposis Hodgkin Lymphoma TP53 Mutation Endometrioid Carcinoma Hereditary Diffuse Gastric Cancer 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Further Reading

  1. Agrawal N et al (2011) Exome sequencing of head and neck squamous cell carcinoma reveals inactivating mutations in NOTCH1. Science 333:1154–1157CrossRefPubMedPubMedCentralGoogle Scholar
  2. Ahn SM et al (2014) Genomic portrait of resectable hepatocellular carcinomas: implications of RB1 and FGF19 aberrations for patient stratification. Hepatology 60:1972–1982CrossRefPubMedGoogle Scholar
  3. Brennan CW et al (2013) The somatic genomic landscape of glioblastoma. Cell 155:462–477CrossRefPubMedPubMedCentralGoogle Scholar
  4. Cancer Genome Atlas Research Network (2012a) Comprehensive molecular portraits of human breast tumors. Nature 490:61–70CrossRefGoogle Scholar
  5. Cancer Genome Atlas Research Network (2012b) Integrated genomic analyses of ovarian carcinoma. Nature 474:609–615Google Scholar
  6. Cancer Genome Atlas Research Network (2013a) Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N Engl J Med 368:2059–2074CrossRefGoogle Scholar
  7. Cancer Genome Atlas Research Network (2013b) Comprehensive molecular characterization of clear cell renal cell carcinoma. Nature 499:43–49CrossRefGoogle Scholar
  8. Cancer Genome Atlas Research Network (2014) Comprehensive molecular profiling of lung adenocarcinoma. Nature 511:543–550CrossRefGoogle Scholar
  9. de Snoo FA, Hayward NK (2005) Cutaneous melanoma susceptibility and progression genes. Cancer Lett 230:153–186CrossRefPubMedGoogle Scholar
  10. Ellenson LH, Wu TC (2004) Focus on endometrial and cervical cancer. Cancer Cell 5:533–538CrossRefPubMedGoogle Scholar
  11. El-Rifai W, Powell SM (2002) Molecular biology of gastric cancer. Semin Radiat Oncol 12:128–140CrossRefPubMedGoogle Scholar
  12. Farazi PA, DePinho RA (2006) Hepatocellular carcinoma pathogenesis: from genes to environment. Nat Rev Cancer 6:674–687CrossRefPubMedGoogle Scholar
  13. Gao JJ et al (2013) Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal 6:l1CrossRefGoogle Scholar
  14. Grasso CS et al (2012) The mutational landscape of lethal castration-resistant prostate cancer. Nature 487:239–243CrossRefPubMedPubMedCentralGoogle Scholar
  15. Haluska FG et al (2006) Genetic alterations in signaling pathways in melanoma. Clin Cancer Res 12:2301s–2307sCrossRefPubMedGoogle Scholar
  16. Hussain SP, Schwank J, Staib F, Wang XW, Harris CC (2007) TP53 mutations and hepatocellular carcinoma: insights into the etiology and pathogenesis of liver cancer. Oncogene 26:2166–2176CrossRefPubMedGoogle Scholar
  17. Iyer G et al (2013) Prevalence and co-occurrence of actionable genomic alterations in high-grade bladder cancer. J Clin Oncol 31:3133–3140CrossRefPubMedPubMedCentralGoogle Scholar
  18. Jones S et al (2008) Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science 321:1801–1806CrossRefPubMedPubMedCentralGoogle Scholar
  19. Kangelaris KN, Gruber SB (2007) Clinical implications of founder and recurrent CDH1 mutations in hereditary diffuse gastric cancer. JAMA 297:2410–2411CrossRefPubMedGoogle Scholar
  20. Kondo T, Ezzat S, Asa SL (2006) Pathogenetic mechanisms in thyroid follicular-cell neoplasia. Nat Rev Cancer 6:292–306CrossRefPubMedGoogle Scholar
  21. Linehan WM, Walther MM, Zbar B (2003) The genetic basis of cancer of the kidney. J Urol 170:2163–2172CrossRefPubMedGoogle Scholar
  22. Munger K et al (2004) Mechanisms of human papillomavirus-induced oncogenesis. J Virol 78:11451–11460CrossRefPubMedPubMedCentralGoogle Scholar
  23. Northcott PA et al (2011) Medulloblastoma comprises four distinct molecular variants. JCO 29:1408–1414CrossRefGoogle Scholar
  24. Ohgaki H, Kleihues P (2007) Genetic pathways to primary and secondary glioblastoma. Am J Pathol 170:1445–1453CrossRefPubMedPubMedCentralGoogle Scholar
  25. Rudin CM et al (2012) Comprehensive genomic analysis identifies SOX2 as a frequently amplified gene in small-cell lung cancer. Nat Genet 44:1111–1116CrossRefPubMedPubMedCentralGoogle Scholar
  26. Seshagiri S et al (2012) Recurrent R-spondin fusions in colon cancer. Nature 488:660–664CrossRefPubMedPubMedCentralGoogle Scholar
  27. Sjoblom T et al (2006) The consensus coding sequences of human breast and colorectal cancers. Science 314:268–274CrossRefPubMedGoogle Scholar
  28. Wang K et al (2014) Whole-genome sequencing and comprehensive molecular profiling identify new driver mutations in gastric cancer. Nat Genet 46:573–582CrossRefPubMedGoogle Scholar
  29. Warnakulasuriya KA, Ralhan R (2007) Clinical, pathological, cellular and molecular lesions caused by oral smokeless tobacco – a review. J Oral Pathol Med 36:63–77CrossRefPubMedGoogle Scholar
  30. Wood LD et al (2007) The genomic landscapes of human breast and colorectal cancers. Science 318:1108–1113CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media B.V. 2016

Authors and Affiliations

  • Fred Bunz
    • 1
  1. 1.The Johns Hopkins UniversityBaltimoreUSA

Personalised recommendations